How big a therapeutic challenge is refractory and relapsed acute myeloid leukemia?
The treatment of refractory relapsed acute myeloid leukemia is an ongoing unresolved medical need, for the reason that the prognosis of relapsed patients is unfortunately poor. The prerequisite for prolonging survival is to achieve a second complete remission, which is already a hassle, and then qualify the patient for allogeneic transplantation. And even in spite of such aggressive treatment, long-term survival in these patients is in the 20-25 percent range (patients survive 4 to 5 years).
And how has the picture of diagnosing and treating acute myeloid leukemia ch... To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].Content locked
